- Home
- CNTX vs DUOT Comparison
CNTX vs DUOT Comparison
Compare CNTX & DUOT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNTX
- DUOT
- Stock Information
- Founded
- CNTX 2015
- DUOT 1990
- Country
- CNTX United States
- DUOT United States
- Employees
- CNTX N/A
- DUOT N/A
- Industry
- CNTX Biotechnology: Pharmaceutical Preparations
- DUOT Computer Software: Prepackaged Software
- Sector
- CNTX Health Care
- DUOT Technology
- Exchange
- CNTX Nasdaq
- DUOT Nasdaq
- Market Cap
- CNTX 78.0M
- DUOT 66.3M
- IPO Year
- CNTX 2021
- DUOT N/A
- Fundamental
- Price
- CNTX $0.58
- DUOT $7.82
- Analyst Decision
- CNTX Strong Buy
- DUOT Strong Buy
- Analyst Count
- CNTX 4
- DUOT 2
- Target Price
- CNTX $6.00
- DUOT $11.50
- AVG Volume (30 Days)
- CNTX 164.6K
- DUOT 125.2K
- Earning Date
- CNTX 05-07-2025
- DUOT 05-15-2025
- Dividend Yield
- CNTX N/A
- DUOT N/A
- EPS Growth
- CNTX N/A
- DUOT N/A
- EPS
- CNTX N/A
- DUOT N/A
- Revenue
- CNTX N/A
- DUOT $11,162,390.00
- Revenue This Year
- CNTX N/A
- DUOT $296.46
- Revenue Next Year
- CNTX N/A
- DUOT $43.11
- P/E Ratio
- CNTX N/A
- DUOT N/A
- Revenue Growth
- CNTX N/A
- DUOT 89.27
- 52 Week Low
- CNTX $0.49
- DUOT $2.03
- 52 Week High
- CNTX $2.75
- DUOT $9.27
- Technical
- Relative Strength Index (RSI)
- CNTX 33.91
- DUOT 52.82
- Support Level
- CNTX $0.49
- DUOT $7.51
- Resistance Level
- CNTX $0.71
- DUOT $9.27
- Average True Range (ATR)
- CNTX 0.08
- DUOT 0.85
- MACD
- CNTX -0.02
- DUOT -0.03
- Stochastic Oscillator
- CNTX 33.31
- DUOT 34.12
About CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
About DUOT Duos Technologies Group Inc.
Duos Technologies Group Inc operating under its brand name duostech, designs, develops, deploys and operates intelligent technology solutions supporting rail, logistics and intermodal businesses that streamline operations, improve safety and reduce costs. The company's main offering, the Railcar Inspection Portal (RIP), provides both freight and transit railroad customers and select government agencies the ability to conduct fully automated railcar inspections of trains while they are moving at full speed. It has also developed the Automated Logistics Information System (ALIS) which automates gatehouse operations where transport trucks enter and exit large logistics and intermodal facilities. Its segments are Rail, Commercial, Governments, Banking and AI.